Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price traded up 9.7% on Wednesday . The company traded as high as GBX 6 and last traded at GBX 5.90. Approximately 595,174 shares were traded during trading, an increase of 120% from the average daily volume of 270,738 shares. The stock had previously closed at GBX 5.38.
Allergy Therapeutics Stock Up 9.7%
The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The company has a market capitalization of £373.62 million, a P/E ratio of -6.08, a PEG ratio of -30.70 and a beta of 0.87. The company has a 50 day moving average of GBX 7.49 and a 200-day moving average of GBX 9.68.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
- Meta’s AI Spending Problem Just Found a BlackRock Solution
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
